Insugen R Refil 100 IU Inj 3 ml Cartridge

Insugen R Refil 100 IU Inj 3 ml Cartridge is a prescription-based medication. It is used in the treatment to reduce the level of blood sugar in the body. It primarily treats type 1 and type 2 diabetic mellitus. It is used together with a healthy diet and consistent exercise to control blood sugar levels after a meal. Its active ingredient is Human insulin (100IU), which belongs to the group class of anti diabetic agents. A doctor's Prescription is required to correctly administer the dosage and duration of the medication.

• Reduce blood sugar level

Some patients experience acute and some experience mild symptoms. Consult a healthcare professional If any of the symptoms persist or worsen:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at injection site.

Insugen R Refil 100 IU Inj 3 ml Cartridge should be taken before or after the meal as it is a short acting (regular) human insulin that helps control the rise in blood sugar levels after eating. The dose adjustment must be correctly administered by the healthcare professional. Follow the recommended dosage as prescribed by the doctor. Never overdose or skip the medication as this may increase the risk of side effects which makes the treatment unsafe and less effective.

Insugen R Refil 100 IU Inj 3 ml Cartridge increases glucose uptake into cells by activating glucose transporters (GLUT 4). The medicine reduces the glucose production by the liver and promotes the storage of glucose as glycogen or lowers blood sugar levels.

• Jørgensen, K. H., Hansen, A. K., & Buschard, K. (2000). Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes research and clinical practice, 50(3), 161-167. https://pubmed.ncbi.nlm.nih.gov/32378737/
• Owens, D. R. (1986). Human insulin: clinical pharmacological studies in normal man. Springer Science & Business Media. https://catalog.nlm.nih.gov/discovery/fulldisplay?docid=alma996129413406676&context=L&vid=01NLM_INST:01NLM_INST&lang=en&adaptor=Local%20Search%20Engine&tab=LibraryCatalog&query=lds56%2Ccontains%2CClinical%20Trials%20as%20Topic%2CAND&mode=advanced&offset=130
• Pfützner, A., Mann, A. E., & Steiner, S. S. (2002). Technosphere™/Insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes technology & therapeutics, 4(5), 589-594. https://pubmed.ncbi.nlm.nih.gov/12450439/
• CHRISTIANSEN, J. S., SONNENBERG, G. E., KVERNELAND, A., SCHMITZ, A., CHRISTENSEN, C. K., HERMANSEN, K., ... & DECKERT, T. (1987). Clinical Outcome of Using Insulin at 40 IU/ml and 100 IU/ml in Pump Treatment: Results of a Controlled Multi‐Center Trial. Acta Medica Scandinavica, 222(1), 65-70. https://pubmed.ncbi.nlm.nih.gov/3307309/
• Boehm, B. O., Home, P. D., Behrend, C., Kamp, N. M., & Lindholm, A. (2002). Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabetic Medicine, 19(5), 393-399. https://pubmed.ncbi.nlm.nih.gov/12027927/